🔴Ipamorelin / Tesamorelin | 2/6mg Blend 🏆

The Ipamorelin/Tesamorelin 2mg/6mg blend consists of two distinct growth hormone secretagogues (GHSs) with complementary mechanisms targeting the somatotropic axis and key cellular pathways involved in anabolic signaling, lipolysis, and metabolic regulation. Ipamorelin is a highly selective growth hormone secretagogue receptor (GHS-R1a) agonist with minimal activity on other hormonal axes. Structurally derived from pentapeptides, it mimics endogenous ghrelin while maintaining specificity in stimulating growth hormone (GH) release without significantly affecting cortisol, prolactin, or ACTH levels. It activates the GHS-R1a receptor in the hypothalamic-pituitary axis, leading to increased pulsatile GH secretion, while modulating the cAMP-PKA pathway to enhance GH release via adenylate cyclase signaling. Additionally, it indirectly influences IGF-1 synthesis through hepatotropic GH receptor activation and engages in mTOR and IGF-1 pathway cross-talk, contributing to cellular growth and anabolic processes. With a short half-life of approximately two hours, Ipamorelin exhibits rapid clearance, minimizing prolonged systemic exposure and receptor desensitization.

Tesamorelin, a stabilized synthetic analog of growth hormone-releasing hormone (GHRH), exhibits prolonged stimulation of the GH-IGF-1 axis due to D-amino acid substitutions that enhance its pharmacokinetic stability and prevent enzymatic degradation. By binding to the GHRH receptor in the hypothalamic-pituitary axis, it triggers sustained GH release, activating downstream JAK/STAT and MAPK/ERK signaling pathways, which augment GH receptor-mediated effects in hepatic and peripheral tissues. Tesamorelin also plays a critical role in metabolic modulation, particularly through AMPK activation in adipose tissue, leading to increased lipolysis and fatty acid oxidation while downregulating lipoprotein lipase (LPL). With a prolonged activity duration of approximately eight to twelve hours, Tesamorelin enhances GH pulsatility, maintains elevated IGF-1 levels, and promotes anabolic signaling with additional metabolic benefits.

The combination of Ipamorelin and Tesamorelin capitalizes on two distinct GH-releasing pathways, leading to a synergistic effect that optimizes hormone pulsatility and metabolic regulation. Ipamorelin provides rapid-onset GH pulsatility through ghrelin-mimetic activity, while Tesamorelin sustains GH secretion over an extended duration via GHRH receptor agonism. Their combined metabolic effects include AMPK-linked lipolysis, with Tesamorelin enhancing fat metabolism and Ipamorelin modulating insulin sensitivity. Additionally, the interplay between the mTOR and IGF-1 pathways results in enhanced anabolic signaling and cellular growth. The pharmacokinetic profile of this blend is designed for maximal efficacy, as Ipamorelin’s short half-life ensures rapid clearance, preventing receptor desensitization, while Tesamorelin’s prolonged activity maintains a sustained hormonal response. Through precise receptor selectivity and complementary pharmacodynamics, this blend represents a targeted approach to GH modulation, optimizing both anabolic and metabolic pathways in preclinical and laboratory models.